An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Niraparib (Primary) ; Niraparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors TESARO
- 05 Sep 2019 Planned number of patients changed from 80 to 134.
- 05 Sep 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 05 Sep 2019 Planned primary completion date changed from 1 May 2019 to 1 Dec 2019.